Combining CSF MTBR-tau243 and plasma pTau217 ratio enhances the prediction of continuous regional tau PET burden in early Alzheimer's disease.

ABSTRACT:

Introduction

Tau PET informs Alzheimer's disease (AD) staging but is limited by cost and access. Plasma phosphorylated-to-nonphosphorylated tau217 ratio (pTau217R) predicts amyloid and tau positron emission tomography (PET), while cerebrospinal fluid (CSF) MTBR-tau243 (tryptic form) and its endogenous form (eMTBR-tau243) reflect tau pathology. We evaluated whether combining them improves tau PET prediction in amyloid-positive early AD.

Methods

In the phase III lecanemab trial, plasma pTau217R was available for 242 participants, CSF markers for 80, and both for 57. Tau PET used [¹⁸F]MK6240. Stochastic gradient boosting models included demographics and apolipoprotein E (APOE) ε4, with performance assessed via repeated cross-validation.

Results

Plasma pTau217R

SUBMITTER: Devanarayan V 

PROVIDER: S-EPMC12576466 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature